ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: L04 • ACR Convergence 2022

    Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis

    Maria de la Luz Garcia-Hernandez1, Javier Rangel-Moreno1, Ananta Paine2, Soumyaroop Bhattacharya3, Jeffrey Fox4, Ernest Meyer5, Brian Isett5, Riyue Bao6, Tullia Bruno6 and Christopher Ritchlin7, 1University of Rochester, Rochester, NY, 2ORNA Tx, Southborough, MA, 3Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, 4CMSR, University of Rochester Medical Center, Rochester, NY, 5UPMC Hillman Cancer Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7University of Rochester Medical Center, Rochester, NY

    Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
  • Abstract Number: L02 • ACR Convergence 2022

    Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

    Christopher Ritchlin1, Laura Coates2, Iain McInnes3, Philip J. Mease4, Joseph Merola5, Yoshiya Tanaka6, Akihiko Asahina7, Laure Gossec8, Alice Gottlieb9, Diamant Thaci10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Vish Shende11, Jason Coarse12 and Robert Landewé13, 1University of Rochester Medical Center, Rochester, NY, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 3College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 8Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, 9Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, 13Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
  • Abstract Number: 0387 • ACR Convergence 2022

    Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity

    Marta Ibañez Martinez1, Sonia Pastor Navarro2, Olga Compán Fernández2, Belén Miguel Ibáñez2, Ana Isabel Turrión Nieves2, Susana Gómez Castro1, Olga Martínez González2, Cristina Hidalgo Calleja2, Esther Toledano Martinez3 and Carlos Montilla Morales2, 1Hospital Universitario Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Spain, 3Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: To evaluate the quality of sleep in patients with psoriatic arthritis (PsA) and its relationship with/to clinical variables, activity, functionality, the impact of the…
  • Abstract Number: 0755 • ACR Convergence 2022

    Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients

    Zesheng An1, Xian Zhou1, Yanfeng Li1, Jane Jaquith1, Kathleen McCarthy-Fruin1, Kenneth J. Warrington1, Ali Duarte-Garcia1, Uma Thanarajasingam1, Cornelia M. Weyand2 and Hu Zeng1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA

    Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…
  • Abstract Number: 1024 • ACR Convergence 2022

    Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance

    Philipp Sewerin1, stephanie Knippschild2, Sabrina Tulka2, Xenofon Baraliakos3 and Ralph Brinks2, 1Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 2Chair for Medical Biometry and Epidemiology, Witten, Germany, 3Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million…
  • Abstract Number: 1150 • ACR Convergence 2022

    Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems

    Rochelle Castillo1, Ikjot Sidhu1, Igor Dolgalev1, Ipsita Subudhi1, Di Yan1, Piotr Konieczny1, Brandon Hsieh1, Tinyi Chu2, Rebecca Haberman1, Shanmugapriya Selvaraj1, Tomoe Shiomi1, Rhina Medina1, Parvathy Vasudevanpillai Girija1, Adriana Heguy1, Cynthia Loomis1, Luis Chiriboga1, Shane Meehan1, Christopher Ritchlin3, Maria de la Luz Garcia-Hernandez4, John Carucci1, Andrea Neimann1, Shruti Naik1 and Jose Scher5, 1NYU Langone Health, New York, NY, 2Memorial Sloan Kettering Cancer Center, New York, NY, 3Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 4University of Rochester, West Henrietta, NY, 5New York University School of Medicine, New York, NY

    Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms driving the vast phenotypic spectrum of psoriatic disease.Methods: To better decipher the cellular…
  • Abstract Number: 1425 • ACR Convergence 2022

    Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases

    Ran Jin1, Silvia Kruppert2, Florian Scholz2, Marc Hammer2, Greg Kricorian1, David Collier3 and Jonathan Kay4, 1Amgen, Inc., Thousand Oaks, CA, 2IQVIA, Frankfurt, Germany, 3Amgen Inc., Simi Valley, CA, 4Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA

    Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
  • Abstract Number: 1506 • ACR Convergence 2022

    Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study

    Paras Karmacharya1, Rikesh Chakradhar2, Alexis Ogdie3, John Davis4, Tina Gunderson4, Cassondra Hulshizer4, Kerry Wright4, Megha M. Tollefson5, Ali Duarte-Garcia4, Delamo Bekele4, Hilal Maradit Kremers4, Floranne Ernste4 and Cynthia Crowson6, 1Vanderbilt University, Nashville, TN, 2St. Christopher's Hospital, Philadelphia, 3Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Rochester, 6Mayo Clinic, Eyota, MN

    Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…
  • Abstract Number: 1768 • ACR Convergence 2022

    Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study

    Sanjana Tarannum1, Jessica Widdifield1, C. Fangyun Wang2, Sindhu R. Johnson3, Paula Rochon1 and Lihi Eder4, 1University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…
  • Abstract Number: 2120 • ACR Convergence 2022

    Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis

    Bruce Strober1, Laura Coates2, Jenny Yu3, Katelyn Rowland4, Evan Leibowitz4, Megan Miller5, Alexa Kollmeier6, Shu Li5, Yanli Wang5, Daphne Chan4, Soumya Chakravarty7, Ya-Wen Yang8, May Shawi8, Mark Lebwohl9 and Proton Rahman10, 1Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, USA, San Diego, 4Janssen Scientific Affairs, LLC, Horsham, PA, 5Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA, 6Janssen-Cilag, Research & Development, LLC, San Diego, CA, 7Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, 8Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 9Icahn School of Medicine at Mount Sinai, New York, NY, 10Memorial University, St. John's, NL, Canada

    Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23, inhibiting its function. GUS has been shown…
  • Abstract Number: 2137 • ACR Convergence 2022

    Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis

    Lihi Eder1, Laura Coates2, Peter Nash3, Uta Kiltz4, Ennio Lubrano5, Erin McDearmon-Blondell6, Tianming Gao7 and Alexis Ogdie8, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3School of Medicine, Griffith University, Brisbane, Australia, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, 6AbbVie, Inc., Mettawa, IL, 7AbbVie, Inc., North Chicago, IL, 8Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
  • Abstract Number: 2199 • ACR Convergence 2022

    Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

    Jeffrey Curtis1, Yujie Su2, Cassie Clinton2, Patrick Stewart3, Bryant England4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Bendcare, Boca Raton, FL, 4University of Nebraska Medical Center, Omaha, NE, 5FASTER, Hoover, AL

    Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
  • Abstract Number: 0062 • ACR Convergence 2022

    Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study

    Justin Levinson1, Jonathan Katz2, Yi Chen3, W. Ryan Powell4, Andrea Gilmore-Bykovskyi5, Amy J. Kind6 and Christie Bartels7, 1University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, 2University of Wisconsin Hospitals and Clinics, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Department of Medicine, Department of Biostatistics and Informatics, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, 5University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, 6University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, 7University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…
  • Abstract Number: 0389 • ACR Convergence 2022

    Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study

    Lihi Eder1, Idit Lavi2, Amir Haddad3, Nili Stein4, Ilan feldhamer5, ARNON DOV COHEN5, Walid Saliba2 and Devy Zisman2, 1Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Carmel Medical Center, Haifa, Israel, 3Carmel Medical Centre, Haifa, Israel, 4Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel, 5Clalit Health Services, Tel Aviv, Israel

    Background/Purpose: We assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV2 infection and COVID-19 hospitalizations in patients with psoriatic disease (PsD) and non-psoriatic controls, and…
  • Abstract Number: 0757 • ACR Convergence 2022

    Safety and Effectiveness of Immune Checkpoint Inhibitors Combination versus Single Agent Therapy in Patients with Pre-existing Autoimmune Diseases

    Pankti Reid1, Sabina Sandigursky2, Maria A. Lopez-Olivo3, Juhee Song4, Houssein Safa5, Samuel Cytryn6, Maryam Buni7, Anna Pavlick8, Michelle Krogsgaard, PhD9, Osama Abu-Shawer10, Mehmet Altan11, Jeffrey Weber12, Maria Suarez-Almazor13, Adi Diab14 and Noha Abdel-Wahab14, 1University of Chicago Medical Center, Chicago, IL, 2NYU Langone Health, New York, NY, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4The University of Texas MD Anderson Cancer Center, Houston, TX, 5Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6Memorial Sloan Kettering Cancer Center, New York, NY, 7MD Anderson Cancer Center, Bellaire, TX, 8Medical Oncology, Weill Cornell Medical Center, New York, NY, 9Perlmutter Cancer Center, Department of Pathology, NYU Langone Health, New York, NY, 10Cleveland Clinic Foundation, Cleveland, OH, 11Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 12NYU Langone Medical Center, Laura and Isaac Perlmutter Cancer Center, New York, NY, 13MD Anderson Cancer Center, Houston, TX, 14UT MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Treatment with a combination of immune checkpoint inhibitors (ICI) has promising outcomes in many tumor types but carries higher adverse event risk than ICI…
  • 1
  • 2
  • 3
  • …
  • 60
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences